Verve Therapeutics has started dosing patients ... in what is thought to be the first test in humans of an experimental CRISPR/Cas9 genome editing technique known as base editing.

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

The idea behind the notorious CRISPR-baby scandal, editing reproductive cells or ... idea which is currently being studied in a gene editing clinical trial led by Verve Therapeutics. Not everyone is ...

Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today highlighted its recent pipeline progress and anticipated 2025 milestones.

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

Group Dinner Meeting to be held in New York on February 5 at 6 pm hosted by Truist. Maximize Your Portfolio with Data Driven Insights:Leverage ...

Verve Therapeutics (VERV) shares rallied 18.7% in the last trading session to close at $7.80. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

CRISPR Therapeutics AG ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based ...

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, ...